In section Releases

bioAffinity Technologies Prices $3.2 Million Public Offering

Targeting a total of $3.2 million in gross proceeds, bioAffinity Technologies has priced a public offering of 4,000,000 shares of common stock at $0.80 per share. The Jersey City-based biotechnology firm, which specializes in noninvasive lung cancer diagnostics, expects the transaction to close on or about June 18, 2026.

By Money Talk·June 17, 2026·2 min read·1,508 reads

The offering, facilitated by WallachBeth Capital LLC as the sole placement agent, includes the option for pre-funded warrants in lieu of common stock, priced at $0.793 per warrant. These warrants are immediately exercisable for one share of common stock each. Proceeds from the sale are calculated before deducting agent fees and other associated expenses.

Execution of the offering remains subject to standard closing conditions. The securities are being issued under a registration statement on Form S-1 previously cleared by the Securities and Exchange Commission.

bioAffinity Technologies Prices $3.2 Million Public Offering

Comments (0)